NovaBridge Biosciences (NBP) Payables (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Payables for 8 consecutive years, with $16.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Payables rose 123.35% year-over-year to $16.8 million; the TTM figure through Dec 2025 stood at $16.8 million (up 123.35% YoY), while the FY2025 annual figure was $16.8 million, up 123.35% from the prior year.
• Payables rose to $16.8 million in Q4 2025 per NBP's latest filing, from $15.2 million in the prior quarter.
• Across five years, Payables topped out at $92.8 billion in Q4 2021 and bottomed at $6.5 million in Q2 2025.
• Historically, Payables has averaged $7.2 billion across 5 years, with a median of $16.8 million in 2025.
• Annual changes were most pronounced in 2021 — Payables soared 109616.73% — and 2022, when it plunged 99.89%.
• NovaBridge Biosciences' Payables stood at $92.8 billion in 2021, then slumped by 99.89% to $102.0 million in 2022, then slumped by 47.21% to $53.8 million in 2023, then plunged by 86.01% to $7.5 million in 2024, then jumped by 123.35% to $16.8 million in 2025.
• Business Quant data shows NBP's Payables at $16.8 million in Q4 2025, $15.2 million in Q3 2025, and $6.5 million in Q2 2025.